Biolargo, Inc.
BioLargo, Inc. is a U.S.-based developer and commercializer of environmental technologies, with operations spanning odor control, water treatment, and engineering services. The company sells CupriDyne Clean and related odor/VOC solutions through ONM Environmental, while its BEST subsidiary markets water-treatment technologies such as AEC for PFAS removal, AOS for micro-pollutants, and AROS for industrial water reuse. It also operates BLEST, an engineering business that provides air-quality compliance services and supports internal technology development. BioLargo’s business model combines product sales, service contracts, and technology commercialization, but it remains capital constrained and dependent on external financing to fund growth.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueOdor-control chemicals, delivery systems, and related field services for landfills, wastewater, and municipal sanitation sites.
Third-party branded pet-odor and related odor-control products sold through private-label arrangements.
Proprietary technologies and equipment platforms for PFAS removal, micropollutant treatment, and water reuse.
Air-quality control engineering, installation, maintenance, and compliance services delivered by BLEST.
Products
Reported · share of revenue- Products74.3 %
- Services25.7 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
BioLargo sells to a mix of municipal, industrial, government, and consumer-channel customers. ONM Environmental serves cities, counties, landfills, transfer stations, wastewater treatment facilities, and other industrial sites that need odor and VOC mitigation systems. BLEST’s third-party customers include U.S. Air Force bases and other clients needing air-quality compliance and engineering support, while its internal work supports BioLargo’s own PFAS and battery development programs. The company also sells private-label odor products to third parties, with Pooph representing the most important consumer-oriented revenue stream in recent periods.
Cities, counties, landfills, and transfer stations buy odor-control products and installed systems to reduce nuisance odors and maintain compliance.
Third-party brands buy odor-control formulations and packaging support, with Pooph historically driving a large share of consolidated revenue.
U.S. Air Force bases buy ongoing air-quality control compliance services and related engineering work.
Industrial users and project partners evaluate AEC, AOS, and AROS technologies for PFAS removal, micropollutant treatment, and reuse applications.
BioLargo subsidiaries use BLEST engineering resources to advance proprietary technologies, especially PFAS and battery-related projects.
Strategy
BioLargo is trying to convert its technology portfolio into repeatable commercial revenue through a mix of product sales, service contracts, and third-party distribution. A major strategic theme is to win early PFAS and water-treatment deployments, then use those reference projects to secure larger follow-on contracts and broader market adoption. The company is also trying to expand beyond its own sales infrastructure by using partners and private-label channels, as shown by the Pooph relationship and other distribution efforts. At the same time, management is focused on conserving capital, using contract manufacturers and stock-based compensation where possible, because the business remains dependent on external financing.
Reference projects and early deployments are intended to validate the technology and unlock larger customer wins.
Recurring municipal and industrial service contracts provide more stable revenue than one-off product sales.
Partner-led channels can scale revenue without requiring BioLargo to build a large internal sales force.
The company has limited liquidity and needs to fund growth without overextending its balance sheet.
Geography
BioLargo is headquartered in the United States and its reported commercial activity is primarily domestic. The company specifically cites ongoing contracts with cities and counties in Southern California, which makes that region important for odor-control revenue and field deployment. BLEST also performs work at U.S. Air Force bases across the country, giving the engineering business a broader U.S. footprint tied to government compliance needs. The company’s technology commercialization efforts are U.S.-centric, and its operational exposure is therefore concentrated in domestic municipal, industrial, and defense markets.
Risks
BioLargo faces substantial going-concern and liquidity risk because operating cash flow has been negative and management says current gross profits are not sufficient to fund operations. Revenue concentration is another major issue: the Pooph private-label relationship has historically represented a large share of consolidated revenue, so any decline in that channel can materially affect results. The company also depends on a small number of recurring municipal and government contracts, which can be delayed, renewed slowly, or lost to competitors. More broadly, commercialization risk is high in PFAS and water-treatment markets because customers may require long sales cycles, field validation, and regulatory confidence before adopting new technologies.
Management states that gross profits are not sufficient to fund current operations and that additional capital will be needed.
Exposure: Corporate liquidity and ongoing R&D/commercialization spend
Pooph has represented a large portion of consolidated revenue, so a decline in that relationship can sharply reduce sales and operating income.
Exposure: ONM Environmental and consolidated revenue mix
New water-treatment technologies require validation, reference projects, and customer confidence before scaling.
The company disclosed credit loss expense tied to customer contractual defaults and note receivable issues.
Exposure: Receivables and note receivable balances
Management notes the need for more qualified staff and reliance on contract manufacturers as demand grows.
Exposure: Engineering delivery and product scaling
Accounting
Judgemental itemsThe company sells products, services, and contract-based work, so timing of delivery and milestones affects reported revenue.
Impact: Can create large quarter-to-quarter swings in revenue and margin
Management disclosed credit loss expense from customer defaults and note receivable issues.
Impact: Can materially increase operating losses in affected periods
Debt with equity or derivative features requires fair-value estimates for warrants and conversion features.
Impact: Can create non-cash expense and volatility in earnings and equity
The company regularly issues stock or options to officers and vendors in lieu of cash.
Impact: Reduces cash outflow but increases non-cash compensation expense and dilution
BLEST bills internal BioLargo projects, but those amounts are eliminated in consolidation.
Impact: Affects segment reporting and can obscure underlying external demand
Similar listed companies
Publicly listed companies with a comparable business focus.
Bion Environmental Technologies Inc
BNET · Agricultural Chemicals
Bion Environmental Technologies is a U.S.-based agricultural environmental technology company focused on making livestock production and organic waste treatment more sustainable.
PERRIGO Co plc
PRGO · Pharmaceutical Preparations
Perrigo Co plc is a consumer self-care company focused on over-the-counter health and wellness products sold through retail and pharmacy channels.
The Clorox Company
CLX · Specialty Cleaning, Polishing and Sanitation Preparations
The Clorox Company makes household and professional products that sit in everyday routines: bleach and disinfectants, trash bags and wraps, cat litter,…
Emergent BioSolutions Inc.
EBS · Pharmaceutical Preparations
Beyond Air, Inc.
XAIR · Surgical & Medical Instruments & Apparatus
Impact BioMedical, Inc
IBO · Pharmaceutical Preparations
Last updated: 11/08/2026